British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming sales figures in ...

We will deliver our fully reinvigorated portfolio to market efficiently and maximise the considerable commercial potential, ...

My father who passed away a while ago and his estate is going through probate. I would like to give our son a third of what I ...

If you or a loved one took Zantac (ranitidine) and later developed health complications, particularly cancer, you may be ...

GSK is pumping 50 million pounds sterling (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals to more precisely treat immune ...

Every time the name changed, it provided work for local ... greatly to North Carolina’s life science future. Those GSK lab doors rattling shut are also going to open some new ones. New businesses. New ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

The full moon names for each month, why they're named so and what we can expect from these lunar events. Many full moon names date back to Native Americans, of what is now the northern and eastern ...

Together with GSK, the Boston-based research team will focus on understanding how dysfunctional lung epithelial cells initiate and perpetuate the disease, including alveolar type 2 (AT2) cells ...